Advertisement

Topics

AstraZeneca’s Phase 3 Head and Neck Cancer Trial with Imfinzi and Tremelimumab Fails to Meet Primary Endpoints

10:07 EST 7 Dec 2018 | Speciality Pharma Journal

AstraZeneca and MedImmune, its global biologics research and development arm, today announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) …

Original Article: AstraZeneca’s Phase 3 Head and Neck Cancer Trial with Imfinzi and Tremelimumab Fails to Meet Primary Endpoints

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca’s Phase 3 Head and Neck Cancer Trial with Imfinzi and Tremelimumab Fails to Meet Primary Endpoints"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...